|
For Immediate Release 22 April 2005
The Medical House PLC
Sponsorship Agreement with Yorkshire Cricketers
The Medical House plc (“TMH”), (AIM:MLH)
is pleased to announce that it has agreed to sponsor two of Yorkshire
Cricket’s finest prospects Tim Bresnan and Joe Sayers. Both
Tim and Joe are first class talents and the back of their bats
will bear The Medical House name.
The only other player who has been sponsored by The Medical House
is England’s captain, Michael Vaughan.
The Medical House plc (“TMH”), (AIM:MLH) is pleased
to announce that it has agreed to sponsor two of Yorkshire Cricket’s
finest prospects Tim Bresnan and Joe Sayers. Both Tim and Joe
are first class talents and the back of their bats will bear The
Medical House name.
The only other player who has been sponsored by The Medical House
is England’s captain, Michael Vaughan.
Ian Townsend, Chairman, The Medical House PLC, said:
“We are delighted to be associated with two young players
whom I have watched for many years. They are exciting prospects
and have tremendous futures ahead of them.”
- Ends –
For further information
The Medical House PLC
Ian Townsend, Laura Hancock Tel: 0114 261 9011
www.themedicalhouse.com
Notes to Editors:
About Medical House - Market Background
TMH has progressively been developing needle-free devices which
are already successfully used in the market. TMH's device, the
SQ-PEN, has great potential in drug delivery worldwide. TMH also
has several distribution agreements in place for the insulin market
for its range of reusable needle-free injectors.
TMH announced in November 2002 that it had received approval from
the PPA (Prescription Pricing Authority) for the admission of
the mhi-500 needle-free insulin injector to the NHS Drug Tariff,
to be effective from 1 January 2003. This has enabled the mhi-500
device and the related consumables to be prescribed on a free-of-charge
basis to the more than 500,000 people with diabetes in the UK
who inject insulin daily. This makes TMH's device the first needle-free
injection system for liquid pharmaceuticals to be available on
the Drug Tariff.
TMH have many agreements already in place covering large parts
of the world including China and Pakistan which have two of the
world’s largest diabetic populations.
In February 2004, TMH announced a license and supply agreement
with Dechra Plc for needle-free injection system for use with
pet animals.
In January 2005 TMH announced an agreement which it has signed
with Serono, to develop and license a new needle-free delivery
system for the delivery of Serono's human growth hormone products.
The market for Human Growth Hormone drugs is expected to reach
$2.2 billion by 2006 according to AS Insights.
Historically the majority of the Group’s turnover has come
from its orthopaedic company, Eurocut Limited, which designs and
manufactures instruments and systems used in orthopaedic procedures
for many of the world’s leading orthopaedic companies. Eurocut
was established in 1988 and now has a reputation as one of Europe’s
leading orthopaedic instrument businesses. In January 2004, the
company moved into significantly enlarged premises enabling it
to expand sales significantly. This enables Eurocut to take advantage
of a growing orthopaedic market which has an increasing demand
for ever more complex instrumentation to carry out minimally invasive
and image guided procedures.
In January 2005, TMH signed a long-term supply agreement with
De Puy, the orthopaedics division of Johnson and Johnson.
|
